Headquarters
75 KNEELAND STREET, 14TH FLOOR, BOSTON, MA 02111-1901, US
BOSTON, MA, US
AXONIS THERAPEUTICS, INC.
From the company
Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibition within the brain. Its work translates breakthrough discoveries spun out from Boston Children's Hospital, Harvard and Laval University. The company has a proprietary KCC2 discovery engine and began first-in-human trials in 2024 for its first-in-class oral KCC2 potentiator drug, AXN-027, designed to restore functional inhibition to treat epilepsy, pain and other CNS pathologies.
Products & services offered
Capabilities 3
Facilities
Send your requirements
Quantities, certifications, and timing.